Diaceutics (LON:DXRX) Insider Jordan Clark Acquires 117 Shares

Diaceutics PLC (LON:DXRX) insider Jordan Clark purchased 117 shares of the business’s stock in a transaction dated Tuesday, December 23rd. The stock was bought at an average cost of GBX 128 per share, with a total value of £149.76.

Diaceutics Stock Up 1.6%

DXRX stock opened at GBX 130 on Tuesday. The stock has a 50-day simple moving average of GBX 153.61 and a two-hundred day simple moving average of GBX 142.38. Diaceutics PLC has a twelve month low of GBX 106 and a twelve month high of GBX 168. The firm has a market capitalization of £110.01 million, a PE ratio of -72.22 and a beta of 0.58. The company has a quick ratio of 9.92, a current ratio of 4.85 and a debt-to-equity ratio of 0.39.

Diaceutics (LON:DXRX) last released its quarterly earnings data on Tuesday, September 23rd. The company reported GBX (2.84) EPS for the quarter. Diaceutics had a negative net margin of 10.90% and a negative return on equity of 7.15%. On average, equities analysts predict that Diaceutics PLC will post 1.0107919 EPS for the current fiscal year.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.